Blueprint Medicines, a Sanofi company, today announced AYVAKIT® (avapritinib) data showing clinically meaningful outcomes and a well-tolerated long-term safety profile in patients with indolent ...
In the field of neurorehabilitation, nerve injury, resulting from trauma, disease, or iatrogenic factors, often leads to irreversible sensory, motor, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results